SCHEMBL2153254

SCHEMBL2153254

N[N]C(=O)C(N)CCC(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 1/20 0.60
GRM6 O15303 1/20 0.60
GRIN2D O15399 1/20 0.60
GRIN3B O60391 1/20 0.60
GSR P00390 1/20 0.60
CYP1A2 P05177 1/20 0.60
GRIK1 P39086 1/20 0.60
GRM5 P41594 1/20 0.60
GRIA1 P42261 1/20 0.60
GRIA2 P42262 1/20 0.60
GRIA3 P42263 1/20 0.60
SLC1A3 P43003 1/20 0.60
SLC1A2 P43004 1/20 0.60
SLC1A1 P43005 1/20 0.60
GRIA4 P48058 1/20 0.60
GRIN1 Q05586 1/20 0.60
GRIN2A Q12879 1/20 0.60
GRIK2 Q13002 1/20 0.60
GRIK3 Q13003 1/20 0.60
GRIN2B Q13224 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19525766 0.82 GRM8 (0.60) GRM8GRM6GRIN2DGRIN3BGSR
SCHEMBL6413584 0.78 GRM8 (0.56) GRM8GRM6GRIN2DGRIN3BGSR
SCHEMBL4459586 0.77 GRM8 (0.54) GRM8GRM6GRIN2DGRIN3BGSR
D-Glutamate SCHEMBL1332297 0.75 GRM8 (1.00) GRM8GRM6GRIN2DGRIN3BGSR
D-Glutamate SCHEMBL17127348 0.75 GRM8 (1.00) GRM8GRM6GRIN2DGRIN3BGSR
SCHEMBL25384088 0.75 CYP1A2 (0.71) GRM8GRM6GRIN2DGRIN3BGSR
Glutamic Acid SCHEMBL5704264 0.75 GRM8 (1.00) GRM8GRM6GRIN2DGRIN3BGSR
D-Glutamate SCHEMBL1330824 0.75 GRM8 (1.00) GRM8GRM6GRIN2DGRIN3BGSR
D-Glutamate SCHEMBL1330484 0.75 GRM8 (1.00) GRM8GRM6GRIN2DGRIN3BGSR
Glutamic Acid SCHEMBL248800 0.75 GRM8 (1.00) GRM8GRM6GRIN2DGRIN3BGSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1228076-B1 A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF NEWSOUTH INNOVATIONS PTY LTD (AU) 2011-07-06 EP disclosed
US-7674775-B2 Substantially cell membrane impermeable compound and use thereof NEW SOUTH INNOVATIONS PTY LIMITED (AU) 2010-03-09 US disclosed
US-7498406-B2 Substantially cell membrane impermeable compound and use thereof NEW SOUTH INNOVATIONS PTY LIMITED (AU) 2009-03-03 US disclosed
US-7186695-B2 Treatment of arthritis with arsenoxide compounds NEW SOUTH INNOVATIONS PTY LIMITED (AU) 2007-03-06 US disclosed
US-20070037995-A1 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2007-02-15 US disclosed
US-7074766-B1 Substantially cell membrane impermeable compound and use thereof NEW SOUTH INNOVATIONS PTY LIMITED (AU) 2006-07-11 US disclosed
EP-1379233-A4 USE OF A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND FOR TREATING ARTHRITIS UNISEARCH LTD (AU) 2005-10-26 EP disclosed
US-20040138102-A1 Use of a substantially cell membrane impermeable compound for treating arthritis NEW SOUTH INNOVATIONS PTY LIMITED (AU) 2004-07-15 US disclosed
EP-1379233-A1 USE OF A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND FOR TREATING ARTHRITIS UNISEARCH LIMITED (AU) 2004-01-14 EP disclosed
WO-2003003011-A1 MODIFICATION OF ANGIOGENESIS BY TARGETING PROTEIN TYROSINE PHOSPHATASES UNISEARCH LIMITED (AU) 2003-01-09 WO disclosed
EP-1228076-A4 A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF UNISEARCH LTD (AU) 2002-11-06 EP disclosed
WO-2002074305-A1 USE OF A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND FOR TREATING ARTHRITIS UNISEARCH LIMITED (AU) 2002-09-26 WO disclosed
EP-1228076-A1 A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF UNISEARCH LIMITED (AU) 2002-08-07 EP disclosed
WO-2001021628-A1 A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF UNISEARCH LIMITED (AU) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037995-A1 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants QSOX1, GSS, SSB GRM8 1978/4885GRM6 2134/4885GRIN2D 2533/4885
US-20040138102-A1 Use of a substantially cell membrane impermeable compound for treating arthritis CD47, SLC7A1, SLC26A3 GRM8 3016/4885GRM6 2933/4885GRIN2D 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.